Improving CAR T-cell therapy for children with leukemia
Official title: Improving CAR T-cell therapy for Pediatric B-cell Acute Lymphoblastic Leukemia (B-ALL)
Funded at St. Jude Children's Research Hospital · NIH-10807843 · Data updated 2026-11-12
This study is looking at a new kind of CAR T-cell therapy for kids with B-cell Acute Lymphoblastic Leukemia (B-ALL) to see if using special donor cells can make the treatment safer and more effective, while also helping the cells stay in the body longer to keep the cancer from coming back.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | St. Jude Children's Research Hospital NIH-funded |
| Lab location | 1 site (Memphis, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $289,458 |
| NIH project number | 1K08CA279927-01A1 |
| Project ID | NIH-10807843 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are pediatric patients under 21 years of age diagnosed with B-cell Acute Lymphoblastic Leukemia.
✕Less likely to help
Patients with other types of leukemia or those over the age of 21 may not benefit from this research.
What this research studies
This research focuses on enhancing CAR T-cell therapy specifically for pediatric patients suffering from B-cell Acute Lymphoblastic Leukemia (B-ALL). The approach involves testing a new type of CAR T-cell product that uses donor memory T-cells to reduce the risk of complications while aiming to improve treatment outcomes. The study will also explore dual-antigen targeting to help maintain remission and enhance the persistence of the CAR T-cells in the body. Patients will be closely monitored through a Phase I clinical trial to gather data on the effectiveness and safety of these innovative therapies.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for children with high-risk leukemia.
How similar studies have gone: Previous research has shown promise in CAR T-cell therapies for pediatric leukemia, indicating that this approach has the potential for significant advancements.
Where this research is happening
-
St. Jude Children's Research Hospital
Memphis, United States Active
Researchers
- Principal investigator: Talleur, Aimee C. — St. Jude Children's Research Hospital
- Study coordinator: Talleur, Aimee C.
Related research
Other NIH-funded projects on the same topics.
-
Improving CAR T-cell therapy for pediatric B-ALL
A physician-scientist at St. Jude aims to advance CAR T-cell therapy for children with high-risk B-ALL by testing new donor-derived and enhanced autologous CAR T-cell approaches in early-phase trials.
-
Blocking fatty acid uptake to help CAR-T work better for relapsed B‑cell ALL
This research looks at whether stopping leukemia cells from taking up fatty acids can help CD19 CAR‑T therapy work better for children and young adults with relapsed B‑cell acute lymphoblastic leukemia.
-
Improving CAR-T cell therapy for children with relapsed B-cell leukemia
This study is looking at how blocking certain fatty acids might make CAR-T cell therapy work better for kids and young adults with relapsed B-cell leukemia, especially those with specific gene changes, to help them get better when other treatments haven't worked.
-
Caregiver-led mobile tool to support healthy habits for kids treated for ALL
A caregiver-directed mobile program helps children who were treated for acute lymphoblastic leukemia build healthier daily routines.
-
Genomics of childhood ALL across global populations
A wide-ranging study looks at how inherited genetics influence the risk of childhood acute lymphoblastic leukemia around the world.
-
Genomics of childhood ALL across diverse populations
A large international study will look at why children everywhere get acute lymphoblastic leukemia and how genetics may influence risk.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.